CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
CURRENT ASSETS
Cash and cash equivalents	$ 29,486,909	$ 5,495,478
Trade accounts and grants receivable, net	1,041,856	1,115,209
Inventory	266,022us-gaap_InventoryNet	178,694us-gaap_InventoryNet
Landlord receivable	377,981btx_TenantAllowanceReceivable	0btx_TenantAllowanceReceivable
Prepaid expenses and other current assets	1,231,789	1,160,589
Total current assets	32,404,557us-gaap_AssetsCurrent	7,949,970us-gaap_AssetsCurrent
Equipment, net	2,857,846us-gaap_PropertyPlantAndEquipmentNet	2,997,733us-gaap_PropertyPlantAndEquipmentNet
Deferred license and consulting fees	336,833btx_DeferredLicenseAndConsultingFees	444,833btx_DeferredLicenseAndConsultingFees
Deposits	443,289us-gaap_DepositsAssetsNoncurrent	129,129us-gaap_DepositsAssetsNoncurrent
Other long-term assets	9,985us-gaap_OtherAssetsNoncurrent	0us-gaap_OtherAssetsNoncurrent
Intangible assets, net	38,848,396	46,208,085
TOTAL ASSETS	74,900,906us-gaap_Assets	57,729,750us-gaap_Assets
CURRENT LIABILITIES
Accounts payable and accrued liabilities	6,803,173	6,722,624
Capital lease liability, current portion	57,500us-gaap_CapitalLeaseObligationsCurrent	0us-gaap_CapitalLeaseObligationsCurrent
Related party convertible debt, net of discount	60,237	0
Deferred license and subscription revenue, current portion	208,357us-gaap_DeferredRevenueCurrent	235,276us-gaap_DeferredRevenueCurrent
Total current liabilities	7,129,267us-gaap_LiabilitiesCurrent	6,957,900us-gaap_LiabilitiesCurrent
LONG-TERM LIABILITIES
Deferred tax liability net	4,514,362	8,277,548
Deferred rent liabilities	97,280us-gaap_DeferredRentCreditNoncurrent	35,997us-gaap_DeferredRentCreditNoncurrent
Lease liabilities	377,981btx_LandlordLiabilities	0btx_LandlordLiabilities
Capital lease, net of current portion	31,290	0
Other long term liabilities	27,961us-gaap_OtherLiabilitiesNoncurrent	195,984us-gaap_OtherLiabilitiesNoncurrent
Total long-term liabilities	5,048,874us-gaap_LiabilitiesNoncurrent	8,509,529us-gaap_LiabilitiesNoncurrent
Commitments and contingencies
SHAREHOLDERS' EQUITY
Preferred shares, no par value, authorized 2,000,000 shares as of December 31, 2014 and 2013; 70,000 and none issued and outstanding as of December 31, 2014 and 2013, respectively	3,500,000us-gaap_PreferredStockValue	0us-gaap_PreferredStockValue
Common shares, no par value, authorized 125,000,000 shares as of December 31, 2014 and 2013; 83,121,698 issued and 78,227,756 outstanding as of December 31, 2014 and 67,412,139 issued and 56,714,424 outstanding as of December 31, 2013	234,842,998us-gaap_CommonStockValue	203,456,401us-gaap_CommonStockValue
Contributed capital	7,145us-gaap_AdditionalPaidInCapital	93,972us-gaap_AdditionalPaidInCapital
Accumulated other comprehensive income	185,835	62,899
Accumulated deficit	(182,190,207)	(145,778,547)
Treasury stock at cost: 4,893,942 and 10,697,715 shares at December 31, 2014 and 2013, respectively	(19,889,788)us-gaap_TreasuryStockValue	(43,033,957)us-gaap_TreasuryStockValue
BioTime shareholders' equity	36,455,983us-gaap_StockholdersEquity	14,800,768us-gaap_StockholdersEquity
Non-controlling interest	26,266,782us-gaap_MinorityInterest	27,461,553us-gaap_MinorityInterest
Total shareholders' equity	62,722,765	42,262,321
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 74,900,906	$ 57,729,750

Carrying amounts as of the balance sheet of deferred license and consulting fees, which consists of the value of warrants issued to third parties for services and to the minority shareholder in BioTime Asia for consulting services, and deferred license fees paid to acquire rights to use the proprietary technologies of third parties.

No definition available.